Lmcg Investments LLC Has $9.23 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lmcg Investments LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 63.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,370 shares of the specialty pharmaceutical company's stock after acquiring an additional 28,907 shares during the period. Lmcg Investments LLC owned approximately 0.12% of Jazz Pharmaceuticals worth $9,233,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 5.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 37,802 shares of the specialty pharmaceutical company's stock worth $4,693,000 after purchasing an additional 1,908 shares in the last quarter. Merit Financial Group LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $281,000. Parallel Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares during the period. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 20,224.5% during the 1st quarter. GAMMA Investing LLC now owns 126,012 shares of the specialty pharmaceutical company's stock valued at $15,644,000 after purchasing an additional 125,392 shares during the period. Finally, Quent Capital LLC raised its stake in shares of Jazz Pharmaceuticals by 56.9% in the 1st quarter. Quent Capital LLC now owns 339 shares of the specialty pharmaceutical company's stock worth $42,000 after buying an additional 123 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now directly owns 100,000 shares in the company, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Robert Iannone sold 2,403 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $138.41, for a total transaction of $332,599.23. Following the transaction, the chief marketing officer now owns 79,621 shares in the company, valued at approximately $11,020,342.61. The trade was a 2.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,543 shares of company stock valued at $845,628 in the last quarter. Insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on JAZZ shares. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday. Cantor Fitzgerald cut Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Stock Up 2.1%

Shares of JAZZ traded up $2.33 during mid-day trading on Friday, hitting $111.13. 726,472 shares of the company's stock were exchanged, compared to its average volume of 837,506. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The firm has a fifty day moving average of $108.37 and a two-hundred day moving average of $121.04. The stock has a market cap of $6.85 billion, a price-to-earnings ratio of 15.65, a P/E/G ratio of 1.04 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.68 earnings per share. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.